Loading…

Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment

Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from > 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchym...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2021-05, Vol.23 (1), p.56-56, Article 56
Main Authors: Dinca, Simion C, Greiner, Daniel, Weidenfeld, Keren, Bond, Laura, Barkan, Dalit, Jorcyk, Cheryl L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3
cites cdi_FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3
container_end_page 56
container_issue 1
container_start_page 56
container_title Breast cancer research : BCR
container_volume 23
creator Dinca, Simion C
Greiner, Daniel
Weidenfeld, Keren
Bond, Laura
Barkan, Dalit
Jorcyk, Cheryl L
description Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from > 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME. Bioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM. Our studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion. Aligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.
doi_str_mv 10.1186/s13058-021-01430-x
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c926db2723da4cd9ba3e1cc708c2e8f9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A665435426</galeid><doaj_id>oai_doaj_org_article_c926db2723da4cd9ba3e1cc708c2e8f9</doaj_id><sourcerecordid>A665435426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3</originalsourceid><addsrcrecordid>eNptUk1v1DAUjBCIlsIf4IAsceklxZ-JwwGpWhWotGUPgNSb5dgvW68Se7GTarnyy3G6pXQR8sF-zzNjvfEUxWuCzwiR1btEGBayxJSUmHCGy92T4pjwSpSC0-unj85HxYuUNhiTWgr5vDhiHBPCsTgufn0Jt9CjAcyN9i4NqAsRrb5eldsYhjCCRbAbozbQ91OvIxr0GN0ORRiChd75NXIetRF0GpHR3kB8j5ar6yVF0zbCOnNGFzzS3qI0tQl-TOBHdLG4Qrp3az_k6mXxrNN9glf3-0nx_ePFt8Xncrn6dLk4X5ZGVGwsK9LIupZdB5jVjGrNMa6pFhwDqXXbVLSu6kZIoLjNMAAjqQBtiRCk5sKyk-Jyr2uD3qhtdIOOP1XQTt01QlwrHUdnelCmoZVtaU2Z1dzYptUMiDE1loaC7Jqs9WGvtZ3aAazJY0TdH4ge3nh3o9bhVknCKCcyC5zeC8SQPUmjGlyaXdYewpQUFbRpCKVifuvtP9BNmKLPVs0oKRvRcPIXtdZ5AOe7MH_bLKrOq0pwlnNQZdTZf1B5WRicCR46l_sHBLonmBhSitA9zEiwmlOo9ilUOYXqLoVql0lvHrvzQPkTO_Ybg4zYdw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528895941</pqid></control><display><type>article</type><title>Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment</title><source>PubMed Central database</source><source>ProQuest Publicly Available Content database</source><creator>Dinca, Simion C ; Greiner, Daniel ; Weidenfeld, Keren ; Bond, Laura ; Barkan, Dalit ; Jorcyk, Cheryl L</creator><creatorcontrib>Dinca, Simion C ; Greiner, Daniel ; Weidenfeld, Keren ; Bond, Laura ; Barkan, Dalit ; Jorcyk, Cheryl L</creatorcontrib><description>Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from &gt; 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME. Bioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM. Our studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion. Aligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/s13058-021-01430-x</identifier><identifier>PMID: 34011405</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Amino Acid Oxidoreductases - genetics ; Amino Acid Oxidoreductases - metabolism ; Analysis ; Bioinformatics ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - genetics ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Cell Line, Tumor ; Cell migration ; Collagen ; Collagen (type I) ; Collagen Type I - metabolism ; Confocal microscopy ; Contraction ; Crosslinked polymers ; Cytokines ; Cytoplasm ; Development and progression ; Enzymes ; Epithelial-Mesenchymal Transition - genetics ; Extracellular matrix ; Extracellular Matrix - metabolism ; Female ; Fibers ; Gene expression ; Glycosylation ; Humans ; IL-1β ; Inflammation ; Interleukin 6 ; Invasiveness ; LOXL2 ; Lysyl oxidase ; Medical prognosis ; Medical research ; Medicine, Experimental ; Mesenchyme ; Metastases ; Metastasis ; Motility ; mRNA ; Neoplasm Metastasis ; Oncostatin M ; Oncostatin M - genetics ; Oncostatin M - metabolism ; Oncostatin M - pharmacology ; Oncostatin M Receptor beta Subunit - genetics ; Oncostatin M Receptor beta Subunit - metabolism ; OSM ; Oxidases ; Patients ; Prognosis ; Proteins ; Signal Transduction ; Stroma ; Tumor cells ; Tumor Microenvironment ; Up-Regulation - genetics</subject><ispartof>Breast cancer research : BCR, 2021-05, Vol.23 (1), p.56-56, Article 56</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3</citedby><cites>FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3</cites><orcidid>0000-0001-5715-472X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132418/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2528895941?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34011405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dinca, Simion C</creatorcontrib><creatorcontrib>Greiner, Daniel</creatorcontrib><creatorcontrib>Weidenfeld, Keren</creatorcontrib><creatorcontrib>Bond, Laura</creatorcontrib><creatorcontrib>Barkan, Dalit</creatorcontrib><creatorcontrib>Jorcyk, Cheryl L</creatorcontrib><title>Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from &gt; 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME. Bioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM. Our studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion. Aligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.</description><subject>Amino Acid Oxidoreductases - genetics</subject><subject>Amino Acid Oxidoreductases - metabolism</subject><subject>Analysis</subject><subject>Bioinformatics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - genetics</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cell migration</subject><subject>Collagen</subject><subject>Collagen (type I)</subject><subject>Collagen Type I - metabolism</subject><subject>Confocal microscopy</subject><subject>Contraction</subject><subject>Crosslinked polymers</subject><subject>Cytokines</subject><subject>Cytoplasm</subject><subject>Development and progression</subject><subject>Enzymes</subject><subject>Epithelial-Mesenchymal Transition - genetics</subject><subject>Extracellular matrix</subject><subject>Extracellular Matrix - metabolism</subject><subject>Female</subject><subject>Fibers</subject><subject>Gene expression</subject><subject>Glycosylation</subject><subject>Humans</subject><subject>IL-1β</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Invasiveness</subject><subject>LOXL2</subject><subject>Lysyl oxidase</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Motility</subject><subject>mRNA</subject><subject>Neoplasm Metastasis</subject><subject>Oncostatin M</subject><subject>Oncostatin M - genetics</subject><subject>Oncostatin M - metabolism</subject><subject>Oncostatin M - pharmacology</subject><subject>Oncostatin M Receptor beta Subunit - genetics</subject><subject>Oncostatin M Receptor beta Subunit - metabolism</subject><subject>OSM</subject><subject>Oxidases</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Signal Transduction</subject><subject>Stroma</subject><subject>Tumor cells</subject><subject>Tumor Microenvironment</subject><subject>Up-Regulation - genetics</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAUjBCIlsIf4IAsceklxZ-JwwGpWhWotGUPgNSb5dgvW68Se7GTarnyy3G6pXQR8sF-zzNjvfEUxWuCzwiR1btEGBayxJSUmHCGy92T4pjwSpSC0-unj85HxYuUNhiTWgr5vDhiHBPCsTgufn0Jt9CjAcyN9i4NqAsRrb5eldsYhjCCRbAbozbQ91OvIxr0GN0ORRiChd75NXIetRF0GpHR3kB8j5ar6yVF0zbCOnNGFzzS3qI0tQl-TOBHdLG4Qrp3az_k6mXxrNN9glf3-0nx_ePFt8Xncrn6dLk4X5ZGVGwsK9LIupZdB5jVjGrNMa6pFhwDqXXbVLSu6kZIoLjNMAAjqQBtiRCk5sKyk-Jyr2uD3qhtdIOOP1XQTt01QlwrHUdnelCmoZVtaU2Z1dzYptUMiDE1loaC7Jqs9WGvtZ3aAazJY0TdH4ge3nh3o9bhVknCKCcyC5zeC8SQPUmjGlyaXdYewpQUFbRpCKVifuvtP9BNmKLPVs0oKRvRcPIXtdZ5AOe7MH_bLKrOq0pwlnNQZdTZf1B5WRicCR46l_sHBLonmBhSitA9zEiwmlOo9ilUOYXqLoVql0lvHrvzQPkTO_Ybg4zYdw</recordid><startdate>20210519</startdate><enddate>20210519</enddate><creator>Dinca, Simion C</creator><creator>Greiner, Daniel</creator><creator>Weidenfeld, Keren</creator><creator>Bond, Laura</creator><creator>Barkan, Dalit</creator><creator>Jorcyk, Cheryl L</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5715-472X</orcidid></search><sort><creationdate>20210519</creationdate><title>Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment</title><author>Dinca, Simion C ; Greiner, Daniel ; Weidenfeld, Keren ; Bond, Laura ; Barkan, Dalit ; Jorcyk, Cheryl L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Amino Acid Oxidoreductases - genetics</topic><topic>Amino Acid Oxidoreductases - metabolism</topic><topic>Analysis</topic><topic>Bioinformatics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - genetics</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cell migration</topic><topic>Collagen</topic><topic>Collagen (type I)</topic><topic>Collagen Type I - metabolism</topic><topic>Confocal microscopy</topic><topic>Contraction</topic><topic>Crosslinked polymers</topic><topic>Cytokines</topic><topic>Cytoplasm</topic><topic>Development and progression</topic><topic>Enzymes</topic><topic>Epithelial-Mesenchymal Transition - genetics</topic><topic>Extracellular matrix</topic><topic>Extracellular Matrix - metabolism</topic><topic>Female</topic><topic>Fibers</topic><topic>Gene expression</topic><topic>Glycosylation</topic><topic>Humans</topic><topic>IL-1β</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Invasiveness</topic><topic>LOXL2</topic><topic>Lysyl oxidase</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Motility</topic><topic>mRNA</topic><topic>Neoplasm Metastasis</topic><topic>Oncostatin M</topic><topic>Oncostatin M - genetics</topic><topic>Oncostatin M - metabolism</topic><topic>Oncostatin M - pharmacology</topic><topic>Oncostatin M Receptor beta Subunit - genetics</topic><topic>Oncostatin M Receptor beta Subunit - metabolism</topic><topic>OSM</topic><topic>Oxidases</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Signal Transduction</topic><topic>Stroma</topic><topic>Tumor cells</topic><topic>Tumor Microenvironment</topic><topic>Up-Regulation - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dinca, Simion C</creatorcontrib><creatorcontrib>Greiner, Daniel</creatorcontrib><creatorcontrib>Weidenfeld, Keren</creatorcontrib><creatorcontrib>Bond, Laura</creatorcontrib><creatorcontrib>Barkan, Dalit</creatorcontrib><creatorcontrib>Jorcyk, Cheryl L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dinca, Simion C</au><au>Greiner, Daniel</au><au>Weidenfeld, Keren</au><au>Bond, Laura</au><au>Barkan, Dalit</au><au>Jorcyk, Cheryl L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2021-05-19</date><risdate>2021</risdate><volume>23</volume><issue>1</issue><spage>56</spage><epage>56</epage><pages>56-56</pages><artnum>56</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from &gt; 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME. Bioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM. Our studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion. Aligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>34011405</pmid><doi>10.1186/s13058-021-01430-x</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5715-472X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1465-542X
ispartof Breast cancer research : BCR, 2021-05, Vol.23 (1), p.56-56, Article 56
issn 1465-542X
1465-5411
1465-542X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c926db2723da4cd9ba3e1cc708c2e8f9
source PubMed Central database; ProQuest Publicly Available Content database
subjects Amino Acid Oxidoreductases - genetics
Amino Acid Oxidoreductases - metabolism
Analysis
Bioinformatics
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - genetics
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - pathology
Cell Line, Tumor
Cell migration
Collagen
Collagen (type I)
Collagen Type I - metabolism
Confocal microscopy
Contraction
Crosslinked polymers
Cytokines
Cytoplasm
Development and progression
Enzymes
Epithelial-Mesenchymal Transition - genetics
Extracellular matrix
Extracellular Matrix - metabolism
Female
Fibers
Gene expression
Glycosylation
Humans
IL-1β
Inflammation
Interleukin 6
Invasiveness
LOXL2
Lysyl oxidase
Medical prognosis
Medical research
Medicine, Experimental
Mesenchyme
Metastases
Metastasis
Motility
mRNA
Neoplasm Metastasis
Oncostatin M
Oncostatin M - genetics
Oncostatin M - metabolism
Oncostatin M - pharmacology
Oncostatin M Receptor beta Subunit - genetics
Oncostatin M Receptor beta Subunit - metabolism
OSM
Oxidases
Patients
Prognosis
Proteins
Signal Transduction
Stroma
Tumor cells
Tumor Microenvironment
Up-Regulation - genetics
title Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A52%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20mechanism%20for%20OSM-promoted%20extracellular%20matrix%20remodeling%20in%20breast%20cancer:%20LOXL2%20upregulation%20and%20subsequent%20ECM%20alignment&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Dinca,%20Simion%20C&rft.date=2021-05-19&rft.volume=23&rft.issue=1&rft.spage=56&rft.epage=56&rft.pages=56-56&rft.artnum=56&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/s13058-021-01430-x&rft_dat=%3Cgale_doaj_%3EA665435426%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-6198778ffe03732aa40072a540e17ab962767958e20b78feec825ead1551745d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2528895941&rft_id=info:pmid/34011405&rft_galeid=A665435426&rfr_iscdi=true